In clinical studies, a higher plasma FGF21 concentration has been found in obese patients with metabolic disorders, impaired glucose tolerance, dyslipidemia, nonalcoholic liver disease, and type 2 diabetes [20,21,22]. This evidence concerns the gene FGF21 and metabolic disease.